Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies, Paving the Way for NDA Filings

  • Annovis Bio received FDA clearance to move forward with Phase 3 trials for buntanetap following an End-of-Phase 2 meeting on October 10, 2024.
  • The pivotal trials will investigate buntanetap’s short-term symptomatic effects and potential long-term disease-modifying benefits in early-stage Alzheimer’s disease (“AD”) patients.
  • Annovis Bio is targeting potential NDA submission within one year of the study’s initiation for symptomatic treatment, based on the results of a well-executed 6-month trial.
  • The FDA raised no safety concerns regarding buntanetap and supported the use of its new crystal form in development.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently announced a significant milestone in its drug development process. On October 10, 2024, the company held an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.

Phase 3 Clinical Trials Overview:

  • A 6-month study to confirm buntanetap’s symptomatic effects in early-stage AD patients.
  • An 18-month study aimed at evaluating its long-term potential as a disease-modifying treatment.

The first, 6-month study is slated to begin in Q1 2025. Notably, if the initial 6-month study yields positive results, it may support an NDA submission of buntanetap as a symptomatic treatment within a year of initiation, fast-tracking the drug’s pathway to market.

No Safety Concerns:

During the FDA meeting, the FDA raised no concerns about data involving liver enzymes, drug interactions, pharmacokinetics, or dose selection, and approved the use of the drug’s new crystal form for all upcoming studies.

CEO Statement:

“We are now ready to move into the highly anticipated Phase 3 stage,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “Our priority is to bring the treatment to patients as early as possible, and we are executing the next clinical trial at the highest standards to attain an expedited NDA submission.”

About Annovis Bio, Inc.

Based in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegenerative diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, with the aim of restoring brain function and improving patients’ quality of life.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in Annovis Bio Inc. ANVS. Bookmark the permalink.

Comments are closed.